1 序文
2 範囲と方法論
2.1 本調査の目的
2.2 利害関係者
2.3 データソース
2.3.1 一次ソース
2.3.2 二次ソース
2.4 市場推定
2.4.1 ボトムアップアプローチ
2.4.2 トップダウンアプローチ
2.5 予測方法論
3 エグゼクティブサマリー
4 はじめに
4.1 概要
4.2 主要な業界動向
5 世界の経口タンパク質＆ペプチド市場
5.1 市場概要
5.2 市場実績
5.3 COVID-19 の影響
5.4 市場予測
6 薬物タイプ別市場内訳
6.1 リナクロチド
6.1.1 市場動向
6.1.2 市場予測
6.2 プレカナチド
6.2.1 市場動向
6.2.2 市場予測
6.3 カルシトニン
6.3.1 市場動向
6.3.2 市場予測
6.4 インスリン
6.4.1 市場動向
6.4.2 市場予測
6.5 オクトレオチド
6.5.1 市場動向
6.5.2 市場予測
7 用途別市場
7.1 胃および消化器疾患
7.1.1 市場動向
7.1.2 市場予測
7.2 骨疾患
7.2.1 市場動向
7.2.2 市場予測
7.3 糖尿病
7.3.1 市場動向
7.3.2 市場予測
7.4 ホルモン障害
7.4.1 市場動向
7.4.2 市場予測
8 地域別市場
8.1 北米
8.1.1 米国
8.1.1.1 市場動向
8.1.1.2 市場予測
8.1.2 カナダ
8.1.2.1 市場動向
8.1.2.2 市場予測
8.2 アジア太平洋地域
8.2.1 中国
8.2.1.1 市場動向
8.2.1.2 市場予測
8.2.2 日本
8.2.2.1 市場動向
8.2.2.2 市場予測
8.2.3 インド
8.2.3.1 市場動向
8.2.3.2 市場予測
8.2.4 韓国
8.2.4.1 市場動向
8.2.4.2 市場予測
8.2.5 オーストラリア
8.2.5.1 市場動向
8.2.5.2 市場予測
8.2.6 インドネシア
8.2.6.1 市場動向
8.2.6.2 市場予測
8.2.7 その他
8.2.7.1 市場動向
8.2.7.2 市場予測
8.3 欧州
8.3.1 ドイツ
8.3.1.1 市場動向
8.3.1.2 市場予測
8.3.2 フランス
8.3.2.1 市場動向
8.3.2.2 市場予測
8.3.3 英国
8.3.3.1 市場動向
8.3.3.2 市場予測
8.3.4 イタリア
8.3.4.1 市場動向
8.3.4.2 市場予測
8.3.5 スペイン
8.3.5.1 市場動向
8.3.5.2 市場予測
8.3.6 ロシア
8.3.6.1 市場動向
8.3.6.2 市場予測
8.3.7 その他
8.3.7.1 市場動向
8.3.7.2 市場予測
8.4 ラテンアメリカ
8.4.1 ブラジル
8.4.1.1 市場動向
8.4.1.2 市場予測
8.4.2 メキシコ
8.4.2.1 市場動向
8.4.2.2 市場予測
8.4.3 その他
8.4.3.1 市場動向
8.4.3.2 市場予測
8.5 中東およびアフリカ
8.5.1 市場動向
8.5.2 国別の市場内訳
8.5.3 市場予測
9 推進要因、阻害要因、および機会
9.1 概要
9.2 推進要因
9.3 阻害要因
9.4 機会
10 バリューチェーン分析
11 ポーターのファイブフォース分析
11.1 概要
11.2 買い手の交渉力
11.3 売り手の交渉力
11.4 競争の度合い
11.5 新規参入の脅威
11.6 代替品の脅威
12 価格分析
13 競合状況
13.1 市場構造
13.2 主要企業
13.3 主要企業のプロフィール
Amryt Pharma Plc
AstraZeneca PLC
Biocon Limited
Novo Nordisk A/S
Oramed Ltd
Proxima Concepts Limited

The global oral proteins and peptides market size was valued at USD 1.8 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 3.4 Billion by 2033, exhibiting a CAGR of 7.13% from 2025-2033. North America currently dominates the market, holding a market share of over 97.8% in 2024. The market is growing due to advancements in drug delivery technologies and the rising demand for non-invasive treatments. Key drivers include the increasing prevalence of chronic diseases like diabetes and cancer coupled with ongoing collaborations between biotech firms and research institutions fostering innovation.

Proteins and peptides are natural components of the human body and play essential roles in many biological processes. Due to their complex structure and susceptibility to digestion in the stomach and small intestine, they are usually administered through injections. However, oral proteins and peptides can be taken via the oral path to treat hormonal, gastric, and metabolic disorders. They are designed to overcome these challenges by using specialized formulations that protect the molecules from digestion and allow them to be absorbed through the intestinal wall into the bloodstream. These formulations include enteric coatings, nanoparticles, and other delivery technologies. Oral proteins and peptides are extensively utilized to treat numerous chronic diseases, such as diabetes, cancer, and autoimmune disorders.

Oral Proteins and Peptides Market Trends:
The increasing volume of patients suffering from chronic diseases, such as cancer, diabetes, cardiovascular disorders (CVDs), and acquired immunodeficiency syndrome (AIDs), and the expanding geriatric population represent the key factors driving the oral proteins and peptides market growth. Besides this, shifting preferences and the rising demand for effective oral drugs and technology among the masses are contributing to the market growth. Moreover, the escalating consumer health consciousness and the growing awareness of the numerous benefits associated with the consumption of oral protein and peptide supplements are creating a positive outlook for the market. In addition to this, innovative technological advancements, such as three-dimensional (3D) printing, nanotechnology, and genetic engineering, have enabled manufacturers to produce more advanced and cost-effective product variants, which is acting as another significant growth-inducing factor. Concurrent with this, the extensive collaborative efforts between pharmaceutical companies, significant advancements in the healthcare infrastructure, and rising research and development (R&D) activities are presenting remunerative growth opportunities for the market. Furthermore, the inflating disposable income of consumers, the widespread adoption of protein-rich diets, the surging demand for protein powder, bars, and shakes, and the increasing proliferation of online platforms providing easy product access are aiding in market expansion.

Oral Proteins and Peptides Industry Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global oral proteins and peptides market, along with forecasts at the global, regional, and country levels from 2025-2033. The market has been categorized based on drug type, application and region.

Drug Type Insights:

Linaclotide
Plecanatide
Calcitonin
Insulin
Octreotide

The report has provided a detailed breakup and analysis of the oral proteins and peptides market based on the drug type. This includes linaclotide, plecanatide, calcitonin, insulin, and octreotide. According to the report, insulin represented the largest segment.

Application Insights:

Gastric and Digestive Disorders
Bone Diseases
Diabetes
Hormonal Disorders

A detailed breakup and analysis of the oral proteins and peptides market based on the application has also been provided in the report. This includes gastric and digestive disorders, bone diseases, diabetes, and hormonal disorders. According to the report, diabetes accounted for the largest market share.

Regional Insights:

North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for oral proteins and peptides. Some of the factors driving the North America oral proteins and peptides market included the increasing prevalence of chronic diseases, the shifting consumer preference for oral drugs, and innovative product advancements.

Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global oral proteins and peptides market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Amryt Pharma Plc, AstraZeneca PLC, Biocon Limited, Novo Nordisk A/S, Oramed Ltd, Proxima Concepts Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

1.How big is the oral proteins and peptides market?
2.What is the future outlook of oral proteins and peptides market?
3.What are the key factors driving the oral proteins and peptides market?
4.Which region accounts for the largest oral proteins and peptides market share?
5.Which are the leading companies in the global oral proteins and peptides market?


1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Oral Proteins and Peptides Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Type
6.1 Linaclotide
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Plecanatide
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Calcitonin
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Insulin
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Octreotide
6.5.1 Market Trends
6.5.2 Market Forecast
7 Market Breakup by Application
7.1 Gastric and Digestive Disorders
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Bone Diseases
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Diabetes
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Hormonal Disorders
7.4.1 Market Trends
7.4.2 Market Forecast
8 Market Breakup by Region
8.1 North America
8.1.1 United States
8.1.1.1 Market Trends
8.1.1.2 Market Forecast
8.1.2 Canada
8.1.2.1 Market Trends
8.1.2.2 Market Forecast
8.2 Asia-Pacific
8.2.1 China
8.2.1.1 Market Trends
8.2.1.2 Market Forecast
8.2.2 Japan
8.2.2.1 Market Trends
8.2.2.2 Market Forecast
8.2.3 India
8.2.3.1 Market Trends
8.2.3.2 Market Forecast
8.2.4 South Korea
8.2.4.1 Market Trends
8.2.4.2 Market Forecast
8.2.5 Australia
8.2.5.1 Market Trends
8.2.5.2 Market Forecast
8.2.6 Indonesia
8.2.6.1 Market Trends
8.2.6.2 Market Forecast
8.2.7 Others
8.2.7.1 Market Trends
8.2.7.2 Market Forecast
8.3 Europe
8.3.1 Germany
8.3.1.1 Market Trends
8.3.1.2 Market Forecast
8.3.2 France
8.3.2.1 Market Trends
8.3.2.2 Market Forecast
8.3.3 United Kingdom
8.3.3.1 Market Trends
8.3.3.2 Market Forecast
8.3.4 Italy
8.3.4.1 Market Trends
8.3.4.2 Market Forecast
8.3.5 Spain
8.3.5.1 Market Trends
8.3.5.2 Market Forecast
8.3.6 Russia
8.3.6.1 Market Trends
8.3.6.2 Market Forecast
8.3.7 Others
8.3.7.1 Market Trends
8.3.7.2 Market Forecast
8.4 Latin America
8.4.1 Brazil
8.4.1.1 Market Trends
8.4.1.2 Market Forecast
8.4.2 Mexico
8.4.2.1 Market Trends
8.4.2.2 Market Forecast
8.4.3 Others
8.4.3.1 Market Trends
8.4.3.2 Market Forecast
8.5 Middle East and Africa
8.5.1 Market Trends
8.5.2 Market Breakup by Country
8.5.3 Market Forecast
9 Drivers, Restraints, and Opportunities
9.1 Overview
9.2 Drivers
9.3 Restraints
9.4 Opportunities
10 Value Chain Analysis
11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 Amryt Pharma Plc
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.2 AstraZeneca PLC
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.2.3 Financials
13.3.2.4 SWOT Analysis
13.3.3 Biocon Limited
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.3.3 Financials
13.3.3.4 SWOT Analysis
13.3.4 Novo Nordisk A/S
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.4.3 Financials
13.3.4.4 SWOT Analysis
13.3.5 Oramed Ltd
13.3.5.1 Company Overview
13.3.5.2 Product Portfolio
13.3.5.3 Financials
13.3.6 Proxima Concepts Limited
13.3.6.1 Company Overview
13.3.6.2 Product Portfolio

*** 経口タンパク質＆ペプチドの世界市場に関するよくある質問(FAQ) ***

・経口タンパク質＆ペプチドの世界市場規模は？
→IMARC社は2024年の経口タンパク質＆ペプチドの世界市場規模を18億米ドルと推定しています。

・経口タンパク質＆ペプチドの世界市場予測は？
→IMARC社は2033年の経口タンパク質＆ペプチドの世界市場規模を34億米ドルと予測しています。

・経口タンパク質＆ペプチド市場の成長率は？
→IMARC社は経口タンパク質＆ペプチドの世界市場が2025年～2033年に年平均7.1%成長すると展望しています。

・世界の経口タンパク質＆ペプチド市場における主要プレイヤーは？
→「Amryt Pharma Plc, AstraZeneca PLC, Biocon Limited, Novo Nordisk A/S, Oramed Ltd, Proxima Concepts Limitedなど ...」を経口タンパク質＆ペプチド市場のグローバル主要プレイヤーとして判断しています。

※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、最終レポートの情報と少し異なる場合があります。

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/